Please select a service we provide from the menu.
Login to retrieve or track an existing case.
HIV drug recalled after cancer risk
07/06/2007
Solicitors specialising in prescription drug poisoning will be monitoring the breaking news that an anti-retroviral drug has been recalled after batches were found to contain a potentially carcinogenic substance.
People in Britain and Northern Ireland are being urged to seek medical attention if they have been prescribed with Viracept, while in the meantime has been recalled by the European Medicines Agency. Around 550 patients are believed to have been using the drug in the UK.
Manufactured by Roche, the drug is usually used in first-line HIV therapy, but certain batches have been contaminated with a genotoxic substance, which could lead to cancer.
A spokesman for the Medicines and Healthcare products Regulatory Agency (MHRA) said that it was unclear whether batches of Viracept had been contaminated on purpose.
Viracept, also known as Nelfinavir, is a protease inhibitor, which works by reducing the amount of virus in the body, therefore reducing the risk of developing AIDS-related illnesses.
A statement from the MHRA read: "Patients prescribed Viracept should contact their doctor immediately. They will have to change to another appropriate medicine for their condition.
"The MHRA, in conjunction with the European Medicines Agency and Roche, has issued a drug alert to recall this medicine from the market, to minimise the risk to patients."
Contact us for legal advice
People in Britain and Northern Ireland are being urged to seek medical attention if they have been prescribed with Viracept, while in the meantime has been recalled by the European Medicines Agency. Around 550 patients are believed to have been using the drug in the UK.
Manufactured by Roche, the drug is usually used in first-line HIV therapy, but certain batches have been contaminated with a genotoxic substance, which could lead to cancer.
A spokesman for the Medicines and Healthcare products Regulatory Agency (MHRA) said that it was unclear whether batches of Viracept had been contaminated on purpose.
Viracept, also known as Nelfinavir, is a protease inhibitor, which works by reducing the amount of virus in the body, therefore reducing the risk of developing AIDS-related illnesses.
A statement from the MHRA read: "Patients prescribed Viracept should contact their doctor immediately. They will have to change to another appropriate medicine for their condition.
"The MHRA, in conjunction with the European Medicines Agency and Roche, has issued a drug alert to recall this medicine from the market, to minimise the risk to patients."
Contact us for legal advice
Bookmarks
